{
Novartis AG

Companies

}
001122334455554433221100
001122334455554433221100

nobel prize awarded for protein design and drug developments advance

David Baker, Demis Hassabis, and John Jumper have won the Nobel Prize in Chemistry for their groundbreaking work in computational protein design and structure prediction, significantly advancing drug design capabilities. Alnylam Pharmaceuticals seeks FDA approval for vutrisiran to treat a severe form of transthyretin amyloidosis, while Johnson & Johnson halts a bladder cancer trial for TAR-200. AstraZeneca invests in a preclinical cholesterol-lowering drug, and Astellas acquires rights to an experimental gene therapy for frontotemporal dementia.
BioPharma Dive
United States Dollar Eli Lilly and Company AviadoBio Alnylam Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc. Amgen Inc. Astellas Pharma Inc. Pfizer Inc. BridgeBio Pharma, Inc. Novartis AG AstraZeneca PLC Johnson & Johnson USA SWE JPN BRA HKG John Jumper David Baker Jonathan Gardner Demis Hassabis Jim Wilson Show more
Healthcare, News Article
13:00 09.10.2024

global pharmaceutical and healthcare market projected to reach 1924 billion by 2032

Rising healthcare costs are straining patients, payers, and providers, limiting access to care and pressuring the pharmaceutical industry to maintain lower prices. The global pharmaceuticals and healthcare market is projected to grow from $1,245.88 billion in 2021 to $1,924.24 billion by 2032, driven by technological advances and demographic changes. However, regulatory barriers and increasing costs pose significant challenges to market growth.
businessresearchinsights.com
United States Dollar Hoffmann-La Roche AG Johnson & Johnson Novartis AG Merck & Co., Inc. AbbVie Inc. CAN FRA GBR USA ISR JPN DNK DEU Merck & Co Roche Johnson & Johnson AbbVie Novartis Show more
Healthcare, Market Report
09:00 07.10.2024

swiss stock market opens lower amid declining inflation figures

The Swiss stock market opened lower on Thursday, influenced by a slowdown in consumer price inflation, which rose by 0.8% year-on-year in September. The leading SMI index fell by 0.20%, with 25 of the 30 major stocks declining, while Sandoz, Novartis, and Givaudan were among the few gainers. Analysts anticipate a potential rate cut by the Swiss National Bank in December 2024 due to declining inflation forecasts.
agefi.com
Euro Swiss Franc Australian Dollar Malaysian Ringgit United States Dollar Kühne + Nagel Ltd. Nestlé S.A. Zurich Insurance Group AG Givaudan SA Novartis AG MYS FRA CHE AUS USA John Plassard Brian Mandt Jurus Arthur Airties Britt Hendriksen Show more
TradFi, Market Report
09:00 03.10.2024

german mergers and acquisitions poised for recovery amid economic challenges

The German M&A market is expected to see a significant recovery in 2025, with a projected 20% increase in transactions compared to the previous year, driven by strategic acquisitions and private equity pressures. Cross-border deals will remain high, particularly with U.S. buyers, while sectors like software, AI, and renewable energy are poised for above-average activity. ESG considerations are becoming crucial in M&A decisions, influencing corporate strategies across various industries.
GoingPublic.de
Euro Novartis AG Evonik IP GmbH Covestro AG Novo Nordisk A/S ARE SAU DEU GBR USA FRA Michael R. Drill Novo Nordisk Show more
Finance & Economy, Market Report
09:00 01.10.2024

investing in healthcare and pharmaceutical etfs for long term growth opportunities

Legal & General Investment Management offers two significant ETFs, L&G Healthcare Breakthrough and L&G Pharma Breakthrough, targeting growth in the healthcare and pharmaceutical sectors. These medium-high risk products can enhance diversified portfolios, especially in light of ongoing interest in medical research post-Covid-19. The iShares Healthcare Innovation UCITS ETF stands out on the Italian stock exchange, reflecting strong performance and a focus on healthcare innovation.
Approfondimenti
AstraZeneca PLC Novartis AG Sanofi CHE USA GBR BlackRock Legal & General Investment Management Show more
Finance & Economy, Market Report
09:00 01.10.2024

nestlé stock market decline poses risks for pension fund investors

Nestlé's stock market struggles are affecting pension fund investors, as the company is a key component in many pillar 3a products, including UBS's Vitainvest and ZKB's Frankly range. These funds, heavily influenced by the Swiss Market Index, face challenges due to the uncertain outlook for major index players like Nestlé, Novartis, and Roche. Björn Eberhardt from Luzerner Kantonalbank warns that investors in index products may not see significant price gains under these conditions.
cash.ch
Swiss Franc ZKB Bigler Nestlé S.A. Hoffmann-La Roche AG UBS SA Novartis AG CHE Björn Eberhardt Show more
TradFi, Market Report
09:00 28.09.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.